Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × lorlatinib × Clear all

Phase

Status

Recruiting 5 Active not recruiting 5 Unknown 4 Not yet recruiting 3 Completed 2 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 59 Radiotherapy 54 Paclitaxel 49 Gemcitabine 49 Cyclophosphamide 48 Cisplatin 47 Carboplatin 45 Dexamethasone 37 Bevacizumab 37 Nivolumab 34 Docetaxel 34 Fluorouracil 33 durvalumab 32 Oxaliplatin 32 Rituximab 28 Magnetic Resonance Spectroscopy 28 Leucovorin 27 Drug Therapy 25 Pemetrexed 24 Doxorubicin 24 Capecitabine 23 atezolizumab 21 Cytarabine 20 Radiosurgery 19 Radiation 19 Prednisone 19 Etoposide 19 Bortezomib 17 Irinotecan 16 Cetuximab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948462 2023-12-13

NSCLC

SCRI Development Innovations, LLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡